Guselkumab showed promising results in achieving significant scalp skin clearance among Chinese patients with moderate-to-severe psoriasis, as highlighted in a phase 4 study analysis. In this analysis, super responders (PASI 100) tended to be younger, had lower body weight, and had no prior use of non-biologic systemic therapy.

Psoriasis is a chronic inflammatory disorder characterized by systemic inflammation and elevated circulating levels of pro-inflammatory cytokines.¹ This persistent inflammatory state has been implicated in immune-mediated injury across multiple organ systems, with particular involvement of renal tissues.¹ However, few large-scale studies have evaluated whether psoriasis independently increases the risk of renal complications in type 2 diabetes mellitus (T2DM) patients receiving guideline-directed renoprotective therapies.² A retrospective cohort study was performed by researchers in Texas to compare the risk of diabetic nephropathy, chronic kidney disease (CKD), end-stage renal disease (ESRD), and dialysis in T2DM patients with and without psoriasis who were receiving angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB) or sodium-glucose cotransporter-2 inhibitor (SGLT2i) therapies.² 

IMM-HK-2500001

Limited treatment options are currently available for psoriasis, including topical corticosteroids, oral anti-inflammatory medications, biologic therapies, and phototherapy.¹ Phototherapy is a cost-effective alternative that has demonstrated excellent efficacy and safety, leading to better patient-reported outcomes.¹ Phototherapy also improves cardiovascular biomarkers and does not carry a risk of infection.¹ While a survey of more than 2,500 psoriasis patients and 1,000 dermatologists across the United States revealed that phototherapy remains a preferred treatment option, particularly for home phototherapy among patients, barriers such as inconvenience, accessibility, and insufficient insurance coverage hinder its use.¹

PsO is a chronic immune-mediated inflammatory skin disease characterized by impaired keratinocyte proliferation and differentiation. Deucravacitinib is a first-in-class TYK2 inhibitor approved for the treatment of moderate-to-severe PsO. At a recent symposium chaired by Professor Chan, Hin-Lee Henry, Professor April Armstrong presented the 4-year efficacy and safety data of deucravacitinib from the long-term extension of the POETYK trial programs which underscored the efficacy of deucravacitinib in difficult-to-treat areas such as the scalp. In addition, Dr. Guan, Xin and Dr. Zhang, Zhen-Ying also shared their firsthand clinical experience in managing different PsO patient subgroups with deucravacitinib.

Psoriasis is an immune-mediated inflammatory disease which has been found to influence the hormone levels of pregnant women, with up to 23% of patients experiencing exacerbation during pregnancy and 65% experiencing worsening conditions after delivery.1 Additionally, psoriasis is associated with und

Chronic disease management could be challenging logistically due to commitment and location, especially under the prevailing Coronavirus disease 2019 (COVID-19) pandemic.¹ This brings in the role of telemedicine, which allows patients to receive healthcare services remotely and efficiently, thus fac

Methotrexate is a multi-acting systemic antipsoriatic drug which simultaneously inhibits purine and pyrimidine synthesis, nitric oxide production and the transcription factor nuclear-factor kappa B (NFĸB) which is an inducible transcription factor for the production of pro-inflammatory cytokines and

As suggested by the observational studies from Italy and France presented at the Virtual Annual Congress of the European Academy of Dermatology and Venereology, biologic therapy for psoriasis may be protective to infected patients against severe and fatal COVID-19 although such protective benefit do